Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling

Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling

Authors: Zhou J, You X, Ke M, Ye L, Wu W, Huang P, Lin C
Publication: J Pharm Sci
Keywords: children, disease modeling, gastroplus, IVIVE, mechanistic absorption model, pbbm, PBPK modeling, physiologically based biopharmaceutics
Software: GastroPlus®

Physiologically based pharmacokinetic (PBPK) modeling has unique advantages in investigating the pharmacokinetics of drugs in special populations.

NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models

NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models

Authors: Moquin SA, Simon O, Karuna R, Lakshminarayana SB, Yokokawa F, Wang F, Saravanan C, Zhang J, Day CW, Chan K, Wang QY, Lu S, Dong H, Wan KF, Lim SP, Liu W, Seh CC, Chen YL, Xu H, Barkan DT, Kounde CS, Sim WLS, Wang G, Yeo HQ, Zou B, Chan WL, Ding M, Song JG, Li M, Osborne C, Blasco F, Sarko C, Beer D, Bonamy GMC, Sasseville VG, Shi PY, Diagana TT, Yeung BKS, Gu F
Publication: Sci Transl Med
Keywords: fih, FIHSimulator, first-in-human predictions, gastroplus, IVIVE, pbbm, PBPK modeling, physiologically based biopharmaceutics, physiologically based pharmacokinetics
Software: GastroPlus®

Dengue virus (DENV) is a mosquito-borne flavivirus that poses a threat to public health, yet no antiviral drug is available.

A Curious Case for Development of Kinase Inhibitors as Antigiardiasis Treatments Using Advanced Drug Techniques

A Curious Case for Development of Kinase Inhibitors as Antigiardiasis Treatments Using Advanced Drug Techniques

Authors: Michaels SA, Hennessey KM, Paragas N, Paredez AR, Ojo KK
Publication: ACS Infect Dis
Keywords: admet predictor, biopharmaceutics, gastroplus, mechanistic absorption model, pbbm, PBPK modeling
Software: ADMET Predictor®, GastroPlus®

Giardiasis is a neglected parasitic diarrheal disease that is particularly associated with poverty.

Quantitative analysis of an impact of P-glycoprotein on edoxaban’s disposition using a human physiologically based pharmacokinetic (PBPK) model

Quantitative analysis of an impact of P-glycoprotein on edoxaban’s disposition using a human physiologically based pharmacokinetic (PBPK) model

Authors: Kato T, Mikkaichi T, Yoshigae Y, Okudaira N, Shimizu T, Izumi T, Ando S, Matsumoto Y
Publication: Int J Pharm
Keywords: gastroplus, mechanistic absorption model, nonlinear kinetics, pbbm, PBPK modeling, physiologically based biopharmaceutics, transporters
Software: GastroPlus®

The purpose of this study was to evaluate the impact of P-glycoprotein (P-gp) efflux on edoxaban absorption in gastrointestinal tracts...

Development of PBPK/PD Model to Predict Impact of Genetic Polymorphisms on thePharmacokinetics and Pharmacodynamicsrepresented by receptor/transporter occupancyof CNS drugs

Development of PBPK/PD Model to Predict Impact of Genetic Polymorphisms on thePharmacokinetics and Pharmacodynamicsrepresented by receptor/transporter occupancyof CNS drugs

Authors: Alqahtani S, Kaddoumi A
Publication: Univ. Louisiana Monroe, School of Pharmacy
Keywords: CNS, oral dosing, PBPK modeling, PD models, PK profile
Software: ADMET Predictor®, GastroPlus®

The general workflow of PBPK modeling and simulation of test compounds in normalpatients and patients with genetic variations consisted of the following steps (see Fig. 1)

2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( Part 2A – Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B – Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)

2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( Part 2A – Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B – Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)

Authors: Spitz S, Zhang Y, Fischer S, McGuire K, Sommer U, Amaravadi L, Bandukwala A, Eck S, Garofolo F, Islam R, Jordan G, King L, Saito Y, Sumner G, Terry L, Vitaliti A, Wang YM, Grimaldi C, Joyce A, Palmer R, Andisik M, Araya M, Azadeh M, Baltrukonis D, Elliott R, Haidar S, Kumar S, Mayer A, Neff F, Palackal N, Peng K, Abhari MR, Satterwhite C, Savoie N, Soo C, Vinter S, Welink J, Yan W, Maher K, Lanham D, Bertholet S, Dakappagari N, Gonneau C, Green C, Junker F, Kar S, Patti-Diaz L, Sarikonda S, McCausland M, Teixeira PC, Decman V, Estevam J, Hedrick M, Robert AH, Hopkins G, Tangri S, Wnek R, Dandamudi S, Dasgupta A, Edmison A, Faustino P, McGuinness M, Lima Santos GM, Mirza T, Shakleya D, Stojdl S, Tampal N, Zhang J, Cherry E, Cludts I, Ishii-Watabe A, Kirshner S, Pedras-Vasconcelos J, Shen M, Siggers R, Solstad T, Verthelyi D, Yan H, Zhang L
Publication: Bioanalysis
Keywords: bioanalysis, biomarkers, cell therapy, gene therapy, immunogenicity, vaccine
Division: Regulatory Strategies

The 14th edition of the Workshop on Recent Issues in Bioanalysis (14th WRIB) was held virtually on June 15-29, 2020 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations, and regulatory agencies worldwide.

Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study

Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study

Authors: Hensley M, Bain W, Jacobs J, Nambulli S, Parikh UM, Cillo A, Staines B, Heaps AL, Sobolewski MD, Rennick LJ, Macatangay BJC, Klamar-Blain C, Kitsios GD, Methé B, Somasundaram A, Bruno TC, Cardello C, Shan F, Workman C, Ray P, Ray A, Lee JS, Sethi R, Schwarzmann WE, Ladinsky MS, Bjorkman PJ, Duprex WP, Agha M, Mellors JW, McCormick KD, Morris A, Haidar G
Publication: Clinical Infectious Diseases
Keywords: COVID-19, RNAemia, SARS-CoV-2, severe acute respiratory syndrome-coronavirus 2

A chimeric antigen receptor-modified T-cell therapy recipient developed severe coronavirus disease 2019, intractable RNAemia, and viral replication lasting >2 months.

Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach

Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach

Authors: Gelemanovic A, Vidovic T, Stepanic V, Trajkovic K
Publication: Pharmaceuticals
Keywords: connectivity map, COVID-19, Drug repurposing, host transcriptome, SARS-CoV-2
Software: ADMET Predictor®

A year after the initial outbreak, the COVID-19 pandemic caused by SARS-CoV-2 virus remains a serious threat to global health, while current treatment options are insufficient to bring major improvements.

An In Vitro–In Vivo Simulation Approach for the Prediction of Bioequivalence

An In Vitro–In Vivo Simulation Approach for the Prediction of Bioequivalence

Authors: Vlachou M, Karalis V
Publication: Materials
Keywords: bioequivalence, drug release, in vitro dissolution, modeling and simulation
Software: PKanalix®
Division: Clinical Pharmacology and Pharmacometrics (CPP)

The aim of this study was to develop a new in vitro–in vivo simulation (IVIVS) approach in order to predict the outcome of a bioequivalence study.